A recent meta-analysis and randomized studies have demonstrated that combined chemoradiotherapy is associated with a survival advantage for selected @entity1 with locally advanced unresectable @entity1149 ( @entity1149 ). We conducted a phase II study of combined chemoradiotherapy to find a more effective combination of drugs and radiation than those previously reported for such @entity1 . Between January 1994 and November 1996, 50 previously untreated @entity1 with locally advanced unresectable @entity1149 (stage IIIA with N2 or IIIB disease) were entered in this study. @entity1 were required to have Eastern Cooperative Oncology Group performance status < or = 2, age < or = 75 years and adequate organ function. Treatment consisted of three cycles of @entity900 (20 mg m(-2), days 1-5) and @entity1487 ( @entity1487 ) (500 mg m(-2), days 1-5) every 4 weeks, and concurrent hyperfractionated @entity1514 radiation (1.25 Gy twice daily, with a 6-h interfraction interval; total radiation dose, 62.5-70 Gy). Of the 50 @entity1 entered, 37 (74%) responded to this chemoradiotherapy, including two (4%) with complete response. By a median follow-up time of 41.0 months, 35 @entity1 had died and 15 were still alive. The median time to progression for responding @entity1 was 14.1 months (range, 2.6-51.3+ months). The median survival time was 18.7 months, with a survival rate of 66.0% at 1 year, 46.0% at 2 years and 27.6% at 3 years. Survival outcome was strongly affected by the extent of nodal involvement (median survival time, 27.4 months for N0-2 disease (n = 37) vs 10.7 months for N3 disease (n = 13); P = 0.007). The major @entity137 of treatment were @entity1431 and @entity1398 (> or = Grade 3, 58% and 60% respectively). Other @entity137 of > or = Grade 3 included @entity882 (26%), @entity417 (26%), @entity1209 (16%) and @entity1161 (6%). Treatment-related @entity204 occurred for one @entity1 . Our findings suggest that @entity900 and @entity1487 in combination with concurrent hyperfractionated @entity1514 radiation is effective and feasible for the treatment of locally advanced unresectable @entity1149 . The short-term survival in this study appeared to be more encouraging than those of similar chemoradiation trials. A randomized trial will be needed to compare the combination of @entity900 and @entity1487 with other @entity902 -based regimens together with concurrent hyperfractionated @entity1514 radiation. In addition, in future studies, inclusion criteria for N3 disease with or without supraclavicular involvement should be reconsidered to correctly evaluate the effect of combined chemoradiotherapy for locally advanced unresectable @entity1149 .

A phase II study of @entity900 and @entity1487 with concurrent hyperfractionated @entity1514 radiation for locally advanced XXXX : a preliminary report from the Okayama Lung Cancer Study Group.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anaemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation oesophagitis'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1514 :: ('MESH:D013896', 'Disease') :: ['thoracic'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU', '5-fluorouracil'] @entity1209 :: ('MESH:D020250', 'Disease') :: ['nausea/vomiting']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small-cell lung cancer']
